Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal
Innovent Biologics will receive $650m upfront and could earn up to $9.85bn in additional milestone payments.
Drug Development
FDA grants priority review for Sanofi’s venglustat NDA
Autobahn’s elunetirom receives FDA fast track designation to treat adjunctive bipolar
SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative
Thinning revenues: inside the $14bn Eliquis patent cliff
Next-generation platforms poised to redefine crowded HAE landscape
Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC
